10-Q: FibroGen Reports Q3 2024 Results, Revenue Up 27% Year-Over-Year

FibroGen's Q3 2024 results show a 27% increase in revenue year-over-year, driven by product sales in China, while the company continues to manage costs and navigate a challenging financial landscape.

Summary

• FibroGen's Q3 2024 revenue increased by 27% year-over-year, reaching $152.9 million, primarily driven by roxadustat sales in China.
• The company reported a net loss of $65.6 million for the nine months ended September 30, 2024, a significant improvement compared to the $228 million loss in the same period of 2023.
• Operating costs and expenses decreased by 39% year-over-year, totaling $211.6 million for the nine months ended September 30, 2024, due to reduced clinical trial expenses and cost control efforts.
• Cash and cash equivalents stood at $131 million as of September 30, 2024, a decrease of $88.1 million from December 31, 2023, primarily due to cash used in operations.
• The company is facing substantial doubt about its ability to continue as a going concern within 12 months due to debt covenants and the need to repatriate cash from China or raise additional capital in the U.S.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive revenue growth and cost reduction, the substantial doubt about the company's ability to continue as a going concern and the significant net losses create a negative sentiment. The reliance on a single product and the risks associated with international operations further contribute to the lower score.

Positives

• Roxadustat continues to show strong sales growth in China, with a 34% increase in sales volume in Q3 2024 compared to Q3 2023.
• The company has significantly reduced operating costs and expenses by 39% year-over-year.
• FibroGen is advancing its oncology pipeline with FG-3246, which is expected to enter a Phase 2 trial in Q1 2025.
• The company has received FDA clearance for its investigational new drug application for FG-3165.
• The company has settled outstanding balances with AstraZeneca related to past transactions under the AstraZeneca Master Supply Agreement, resulting in a $25.7 million cumulative catch-up net adjustment to drug product revenue.

Negatives

• The company reported a net loss of $65.6 million for the nine months ended September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern within 12 months.
• Cash and cash equivalents decreased by $88.1 million from December 31, 2023, to $131 million as of September 30, 2024.
• The company recorded a restructuring charge of $18.6 million in Q3 2024 due to a reduction in force.
• The company has terminated the pamrevlumab program, resulting in a write-off of work-in-progress inventory.

Risks

• The company's future success is heavily dependent on the commercial success of roxadustat and the development of FG-3246.
• There is a risk of not obtaining regulatory approval for product candidates in one or more jurisdictions and indications.
• The company faces substantial competition in the development and commercialization of product candidates.
• The company relies on third parties for manufacturing and distribution, which could lead to supply chain disruptions.
• The company's operations in China are subject to regulatory and economic risks, including currency exchange restrictions and potential changes in government policies.
• The company may not be able to repatriate additional cash from its China operations or raise additional capital in the U.S., which could lead to a default on debt covenants.
• The company is subject to various legal proceedings, including securities class action and derivative lawsuits, which could result in significant costs and reputational damage.

Future Outlook

The company expects an approval decision for roxadustat in chemotherapy-induced anemia in China in early 2025 and anticipates initiating a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in the first quarter of 2025.

Management Comments

• Management is evaluating measures to repatriate additional cash from its China operations.
• Management is exploring options to raise additional funds in the U.S. through equity, equity-linked, or debt financing arrangements or from other sources.

Industry Context

The report reflects the ongoing challenges and opportunities in the biopharmaceutical industry, particularly for companies focused on drug development and commercialization in competitive markets like China. The company's focus on oncology and anemia treatments aligns with significant unmet medical needs, but also faces competition from established players and generic manufacturers.

Comparison to Industry Standards

• The revenue growth of 27% year-over-year is a positive sign, but the company's continued losses and cash burn are concerning compared to industry benchmarks for companies at a similar stage.
• The reduction in operating expenses by 39% year-over-year is a significant achievement, indicating effective cost management, but the company's financial position remains precarious.
• The development of FG-3246 for prostate cancer is a positive step, but the company's reliance on a single product for revenue generation is a risk compared to companies with more diversified pipelines.
• The company's reliance on third-party manufacturers and distributors is common in the industry, but the risks associated with single-source suppliers and supply chain disruptions are significant.
• The company's operations in China are subject to unique regulatory and economic risks, which are not typically faced by companies focused solely on the U.S. or European markets.

Legal Proceedings

• The company is a party to various legal actions, including a consolidated putative class action lawsuit and several derivative lawsuits.
• The company has reached an agreement in principle to settle the class action at $28.5 million.
• The company has received a subpoena from the SEC requesting documents related to roxadustats pooled cardiovascular safety data and is currently discussing with the SEC for a potential settlement.

Related Party Transactions

• The company recorded license and development revenue related to collaboration agreements with Astellas of $0.4 million and $2.4 million for the three months ended September 30, 2024 and 2023, and $1.0 million and $5.8 million for the nine months ended September 30, 2024 and 2023, respectively.
• The company recorded drug product revenue from Astellas of $(0.3) million and $1.3 million for the three months ended September 30, 2024 and 2023, and $(0.7) million and $17.7 million for the nine months ended September 30, 2024 and 2023, respectively.
• The net product revenue from Falikang was $42.2 million and $26.5 million for the three months ended September 30, 2024 and 2023, and $115.3 million and $68.3 million for the nine months ended September 30, 2024 and 2023, respectively.
• The investment income in Falikang was $0.9 million and $0.7 million for the three months ended September 30, 2024 and 2023 and $2.7 million and $2.0 million for the nine months ended September 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders face the risk of further stock dilution and potential loss of investment due to the company's financial challenges.
• Employees have been impacted by the reduction in force, resulting in job losses and uncertainty.
• Customers in China may benefit from the continued availability of roxadustat, but the company's financial instability could affect long-term supply.
• Collaboration partners, such as Astellas and AstraZeneca, may be impacted by the company's financial challenges and potential changes in strategy.
• Creditors face the risk of default on debt obligations if the company is unable to raise additional capital or repatriate funds from China.

Next Steps

• The company plans to initiate a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in the first quarter of 2025.
• The company expects an approval decision for roxadustat in chemotherapy-induced anemia in China in early 2025.
• The company will continue to evaluate measures to repatriate additional cash from its China operations.
• The company will continue to explore options to raise additional funds in the U.S.

Key Dates

Keywords

roxadustat, FG-3246, anemia, cancer, clinical trials, China, Astellas, AstraZeneca, revenue, biopharmaceutical, oncology, drug development